SIX$ALC

Alcon Inc. · Q3 2025 earnings

Q3 2025 earnings · · After market close · Investor relations

Briefing

Net sales rise 6% to $2.59B as equipment growth accelerates and Unity VCS gains traction

Alcon reported Q3 2025 results for the period ended September 30, 2025, with net sales of $2.59 billion, up 6% reported and 5% constant currency versus Q3 2024. Surgical net sales increased 6% to $1.42 billion, led by 13% equipment/other growth on Unity VCS and recent launches, while Vision Care net sales rose 7% to $1.17 billion on contact lens and ocular health strength. Operating income was flat at $332 million as incremental tariffs, launch investments and higher R&D offset manufacturing efficiencies. Net income was $237 million and diluted EPS was $0.48 versus $0.53 a year ago on higher tax expense; core diluted EPS was $0.79. The company maintained full-year 2025 guidance of $10.3–10.4 billion in net sales and core diluted EPS of $3.05–3.15.

  • Q3 net sales were $2.59B (+6% reported, +5% cc); Surgical $1.42B (+6%) and Vision Care $1.17B (+7%)
  • Equipment/other surgical sales jumped 13% to $243M on Unity VCS momentum; implantables rose 2% on PanOptix Pro
  • Operating income was flat at $332M; core operating income rose 4% to $523M
  • Diluted EPS was $0.48 (-9%); core diluted EPS was $0.79 (-2%)
  • Full-year 2025 guidance maintained at $10.3–10.4B sales and $3.05–3.15 core diluted EPS

Headline financials

Total Revenue

$2.59B

Previous: $2.43B+6.4%
EPS (adj)

$0.79

Previous: $0.81-2.5%
Core Operating Margin

20.2%

No prior period
Operating margin

12.8%

No prior period
Net Income

$237M

Previous: $263M-9.9%
Operating Income

$332M

Previous: $332M+0.0%
Gross Profit

$1.46B

Previous: $1.37B+6.3%

Revenue & EPS history

Alcon · Revenue · Quarterly

$2.59B

Q3 2025+6.4%vs Q3 2024
Beat estimate in 8 of 16 quarters(50%)
ActualEstimate

Revenue by segment

Alcon · $5.12B total across 6 segments · Q1 2026

  • Surgical
    $1.46B
  • Vision Care
    $1.23B
  • Surgical — Consumables
    $769M
  • Vision Care — Contact lenses
    $738M
  • Vision Care — Ocular health
    $487M
  • Surgical — Implantables
    $438M

Forward guidance

Alcon maintained its previously communicated full-year 2025 outlook after Q3 results.

Tailwinds

  • FY2025 net sales outlook maintained at $10.3–10.4B (+4% to +5% cc)
  • Core diluted EPS guidance maintained at $3.05–3.15
  • Unity VCS orderbook remains strong heading into 2026

Headwinds

  • Operating margin pressured by tariffs and launch-related SG&A/R&D investment
  • Diluted EPS declined 9% YoY on higher tax expense

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

+0.7%

Avg return

Earnings day

-1.8%

Avg return

5 days after

-1.5%

Avg return

30 days after

48%

13 / 27 earnings

Positive

+13.0%

Q2 2021

Best reaction

-8.9%

Q2 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.2%-34.4%-28.6%
Q3 2025+4.6%-1.0%+1.9%
Q2 2025-8.9%-10.4%-14.3%
Q1 2025+2.4%-4.2%-7.6%
Q3 2024-5.2%-7.7%-7.1%
Q2 2024-1.7%-0.2%+2.2%
Q1 2024+8.9%+8.3%+12.5%
Q4 2023+6.4%+7.7%+3.4%
Q3 2023-2.1%-2.1%+7.0%
Q2 2023-1.6%+1.4%+0.4%
Q1 2023+7.6%+6.0%+5.4%
Q4 2022-3.9%-3.7%-4.8%
Q3 2022+4.1%+3.1%+8.1%
Q2 2022-5.4%-7.9%-10.4%
Q1 2022+8.7%+10.0%+12.7%
Q4 2021+5.0%-0.6%-0.3%
Q3 2021-4.2%-5.9%-1.4%
Q2 2021+13.0%+13.9%+21.9%
Q1 2021-7.8%-7.6%-9.0%
Q4 2020-2.1%-4.4%-3.1%
Q3 2020-1.1%-0.3%-1.8%
Q2 2020-2.9%-4.9%-4.1%
Q1 2020+4.3%+5.0%+7.0%
Q4 2019+4.5%+1.4%-20.2%
Q3 2019-3.5%-3.8%-3.0%
Q2 2019-2.0%-5.1%-4.1%
Q1 2019+2.1%-0.4%-3.3%
Q4 2018
Q3 2018
Q2 2018
Q1 2018
Q4 2017
Q4 2011
Q3 2010
Q2 2010
Q1 2009
Q1 2010
Q4 2009
Q4 2007
Q3 2009
Q3 2008
Q4 2008
Q2 2008
Q2 2009

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro